Literature DB >> 6135202

Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients.

A P Roberts, C Harrison, G T Dixon, J R Curtis.   

Abstract

A comparison was made of the plasma concentrations of ranitidine base in 12 normal volunteers after the administration of 100 mg intravenously and in 6 patients with terminal renal failure after 40 mg intravenously off and then during haemodialysis. The plasma ranitidine concentrations were determined by radioimmunoassay. The results suggest that reduced elimination of the drug occurs in patients with severe renal failure and that there is significant removal of the drug during haemodialysis. It is suggested that dosage reduction is advisable in patients with severe renal failure and a suitable schedule for such patients is described.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135202      PMCID: PMC2417372          DOI: 10.1136/pgmj.59.687.25

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  4 in total

1.  Pharmacologically effective plasma concentrations of ranitidine.

Authors:  N R Peden; D A Richards; J H Saunders; K G Wormsley
Journal:  Lancet       Date:  1979-07-28       Impact factor: 79.321

2.  The development of a radioimmunoassay for ranitidine in biological fluids.

Authors:  W N Jenner; L E Martin; B A Willoughby; I Fellows
Journal:  Life Sci       Date:  1981-03-23       Impact factor: 5.037

3.  Inhibition of pentagastrin-stimulated and nocturnal gastric secretion by ranitidine. A new H2-receptor antagonist.

Authors:  N R Peden; J H Saunders; K G Wormsley
Journal:  Lancet       Date:  1979-03-31       Impact factor: 79.321

4.  Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography.

Authors:  P F Carey; L E Martin; P E Owen
Journal:  J Chromatogr       Date:  1981-09-11
  4 in total
  7 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Pharmacokinetics of ranitidine in patients undergoing haemofiltration.

Authors:  U Gladziwa; D R Krishna; U Klotz; T H Ittel; H Schunkert; W M Glöckner; H Mann
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

4.  Ranitidine pharmacokinetics in continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; T Comstock; A Harford; F Eshelman
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 5.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 6.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

Review 7.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.